Trending NewsTrending NewsNASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $18.54 -0.42 (-2.22%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$16.23 -2.32 (-12.49%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$18.45▼$19.2050-Day Range$16.73▼$21.8752-Week Range$11.42▼$25.67Volume3.91 million shsAverage Volume2.54 million shsMarket Capitalization$4.43 billionP/E Ratio21.81Dividend YieldN/APrice Target$27.67Consensus RatingBuy Company Overview ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 87% of companies evaluated by MarketBeat, and ranked 288th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has received no research coverage in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth35.29% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 35.29% in the coming year, from $0.51 to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 21.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.53.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 21.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.44.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 12.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.06% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.06% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.82 News SentimentADMA Biologics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for ADMA Biologics this week, compared to 9 articles on an average week.Search Interest21 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows18 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,644,269.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growthAugust 7 at 2:19 AM | msn.comADMA Biologics Inc (ADMA) Q2 2025 Earnings Report Preview: What To Look ForAugust 7 at 2:19 AM | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 7 at 2:00 AM | Brownstone Research (Ad)Adma Biologics (ADMA) Q2 Revenue Up 14%August 6 at 11:02 PM | fool.comADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call TranscriptAugust 6 at 10:06 PM | seekingalpha.comADMA Biologics Inc earnings missed, revenue fell short of estimatesAugust 6 at 8:36 PM | investing.comADMA Biologics Q2 2025 Earnings: EPS of $0. ...August 6 at 5:13 PM | gurufocus.comADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6 at 4:05 PM | globenewswire.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $17.15 on January 1st, 2025. Since then, ADMA shares have increased by 8.1% and is now trading at $18.54. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings data on Wednesday, May, 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by $0.02. The firm's quarterly revenue was up 40.2% on a year-over-year basis. Read the conference call transcript. Who are ADMA Biologics' major shareholders? Top institutional shareholders of ADMA Biologics include Allspring Global Investments Holdings LLC (1.39%), Perpetual Ltd (1.21%), Vaughan Nelson Investment Management L.P. (0.75%) and Bank of New York Mellon Corp (0.63%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen, Steve Elms and Bryant Fong. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2025Today8/06/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Price Target for ADMA Biologics$27.67 High Price Target$32.00 Low Price Target$25.00 Potential Upside/Downside+49.2%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.85 Trailing P/E Ratio21.81 Forward P/E Ratio36.35 P/E GrowthN/ANet Income$197.67 million Net Margins45.01% Pretax Margin30.64% Return on Equity47.16% Return on Assets30.51% Debt Debt-to-Equity Ratio0.22 Current Ratio6.58 Quick Ratio3.36 Sales & Book Value Annual Sales$426.45 million Price / Sales10.38 Cash Flow$0.53 per share Price / Cash Flow35.03 Book Value$1.48 per share Price / Book12.53Miscellaneous Outstanding Shares238,730,000Free Float230,378,000Market Cap$4.43 billion OptionableOptionable Beta0.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ADMA) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.